Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A DSMB note on an imbalance that is not yet a signal put 505(b)(2) literature-to-product bridge table in front of regulatory-affairs lead in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / CMC and Development Pathways close is to drop a secondary from 505(b)(2) literature-to-product bridge table, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population. 2. 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a DSMB note on an imbalance that is not yet a signal; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for regulatory-affairs lead in a safety team sitting on a new disproportionate signal. 4. 505(b)(2) literature-to-product bridge table is missing the fact regulatory-affairs lead needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform